TG Therapeutics Inc (TGTX): Short Seller Sentiment is Bearish
We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...
The Pharma Letter2d
Strong new data for Briumvi in MS
TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...
Multiple Sclerosis News Today3d
ECTRIMS 2024: MS relapse rates fall with 5 years on Briumvi
Continuous treatment with Briumvi (ublituximab) over five years was associated with low rates of relapses and confirmed ...
Investor's Business Daily on MSN3d
IBD 50's TG Therapeutics Rises On Five-Year Data For Multiple Sclerosis Drug
TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...
TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b Study - Quick Facts
TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...
Benzinga.com3d
What's Going On With TG Therapeutics Stock Wednesday?
TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted in an ...
The Bakersfield Californian4d
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing ...
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...